Immunomodulators for all patients with inflammatory bowel disease?

Therapeutic Advances in Gastroenterology

Volumn 3, Issue 1, 2010, Pages 31-42

  Ardizzone, Sandro ^a   Cassinotti, Andrea ^a   Manes, Gianpiero ^a   Porro, Gabriele Bianchi ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Azathioprine; Crohn's disease; Immunomodulators; Inflammatory bowel disease (IBD); Treatment; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE;

CROHN DISEASE; DRUG EFFICACY; DRUG SAFETY; ENTERITIS; EVIDENCE BASED PRACTICE; FEVER; HEPATITIS; HUMAN; IMMUNOMODULATION; MALAISE; PANCREATITIS; PATHOGENESIS; PATHOPHYSIOLOGY; PATIENT SAFETY; PRIORITY JOURNAL; RASH; REVIEW; ULCERATIVE COLITIS;

EID: 77953381829     PISSN: 1756283X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1756283X09354136     Document Type: Review

References (55)

1. Alfadhli, A.A.F., McDonald, J.W.D. and Feagan, B.G. ( 2004) Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database of Systematic Reviews 4: CD003459. DOI: 10.1002/14651858.CD003459.pub2.
2. Ardizzone, S. and Bianchi Porro, G. ( 2002) Inflammatory bowel disease: new insights into pathogenesis and therapy. J Intern Med 252: 475-496.
3. Ardizzone, S., Bollani, S., Manzionna, G., Imbesi, V., Colombo, E. and Bianchi Porro, G. ( 2003) Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomized, investigator-blind study. Dig Liver Dis 35: 619-627.
4. Ardizzone, S., Maconi, G., Russo, A., Imbesi, V., Colombo, E. and Bianchi Porro, G. ( 2006) Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 55: 47-53.
5. Ardizzone, S., Maconi, G., Sampietro, G.M., Russo, A., Radice, E., Colombo, E. et al. (2004) Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology 127: 730-740.
6. Baert, F., Noman, M., Vermeire, S., Assche, G., D'Haens, G., Carbonz, A. et al. (2003) Influence of immunogenicity on the longterm efficacy of infliximab in Crohn's disease. N Engl J Med 348: 601-608.
7. Beaugerie, L., Carrat, F., Bouvier, A.-M., Brousse, N., Carbonnel, F., Colombel, J.-F. et al. (2008) Excess risk of lymphoproliferative disorders (LPD) in inflammatory bowel disease (IBD): interim results of the CESAME cohort. Gastroenterology 134(Suppl. 1): A116-A177.
8. Beaugerie, L., Seksik, P. and Carrat, F. ( 2009) Thiopurine therapy is associated with a three-fold decrease in the incidence of advanced colorectal neoplasia in IBD patients with longstanding extensive colitis: the CESAME prospective data. J Crohn's Colitis 3: S5 (Abstract).
9. Beaugerie, L., Seksik, P., Nion-Larmurie, I., Gendre, J.P. and Cosnes, J. ( 2006) Predictors of Crohn's disease. Gastroenterology 130: 650-656.
10. Cassinotti, A. and Travis, S. (2009) Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review. Inflamm Bowel Dis 15: 1264-1275.
11. Chande, N., MacDonald, J.K. and McDonald, J.W.D. ( 2007) Methotrexate for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 4: CD006618. DOI: 10.1002/14651858.CD006618.pub2.
12. Colombel, J.F., Sandborn, W.J., Rutgeerts, P., Enns, R., Hanauer, S.B., Panaccione, R. et al. (2007) Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 132: 52-65.
13. D'Haens, G., Geboes, K., Ponette, E., Penninckx, F. and Rutgeerts, P. ( 1997) Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease. Gastroenterology 112: 1475-1481.
14. D'Haens, G., Geboes, K. and Rutgeerts, P. ( 1999) Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine. Gastrointest Endosc 50: 667-671.
15. D'Haens, G.R., Vermeire, S., van Assche, G., Noman, M., Aerden, I., van Olmen, G. et al. (2008) Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroenterology 135: 1123-1129.
16. Dubinsky, M.C. ( 2004) Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety. Clin Gastroenterol Hepatol 2: 731-743.
17. Etchevers, M.J., Aceituno, M. and Sans, M. ( 2008) Are we giving azathioprine too late? The case for early immunomodulation in inflammatory bowel disease. World J Gastroenterol 14: 5512-5518.
18. Feagan, B.G., Fedorak, R.N., Irvine, E.J., Wild, G., Sutherland, L., Steinhart, A.H. et al. (2000) A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. N Engl J Med 342: 1627-1632.
19. Feagan, B.G., McDonald, J.W.D., Panaccione, R., Enns, R., Bernstein, C.N., Ponich, T. et al. (2008) A randomized trial of methotrexate in combination with infliximab for the treatment of Crohn's disease [abstract]. Gut 57(SII): A66.
20. Feagan, B.G., Rochon, J., Fedorak, R.N., Irvine, E.J., Wild, G., Sutherland, L. et al. (1995) Methotrexate for the treatment of Crohn's disease. N Engl J Med 332: 292-297.
21. Fraser, A.G., Orchard, T.R. and Jewell, D.P. ( 2002) The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 50: 485-489.
22. Froslie, K.F., Jahnsen, J., Moum, B.A. and Vatn, M.H. and the IBSEN Group (2007) Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 133: 412-422.
23. Gisbert, J.P., Linares, P.M., Mcnicholl, A.G., Maté, J. and Gomollòn, F. (2009) Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis. Aliment Pharmacol Ther 30: 126-137.
24. Hanauer, S.B., Korelitz, B.I., Rutgeerts, P., Peppercorn, M.A., Thisted, R.A., Cohen, R.D. et al. (2004) Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology 127: 723-729.
25. Hanauer, S.B., Sandborn, W.J., Rutgeerts, P., Fedorak, R.N., Lukas, M., MacIntosh, D. et al. (2006) Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 130: 323-333.
26. Herfarth, H., Tjaden, C., Lukas, M., Obermeier, F., Dilger, K., Muller, R. et al. (2006) Adverse events in clinical trials with azathioprine and mesalamine for prevention of postoperative recurrence of Crohn's disease. Gut 55: 1525-1526.
27. Kandiel, A., Fraser, A.G., Korelitz, B.I., Bresinger, C. and Lewis, J.D. ( 2005) Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 54: 1121-1125.
28. Korzenik, J.R. and Podolsky, D.K. ( 2006) Evolving knowledge and therapy of inflammatory bowel disease. Nat Rev Drug Discov 5: 197-209.
29. Langholz, E., Munkholm, P., Davidsen, M. and Binder, V. ( 1994) Course of ulcerative colitis: analyis of changes in disease activity over years. Gastroenterology 107: 3-11.
30. Lewis, J., Schwartz, S. and Lichtenstein, G.R. ( 2000) Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma. Gastroenterology 118: 1018-1024.
31. Lichtenstein, G.R., Abreu, M.T., Cohen, R. and Tremaine, W. ( 2006) American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 130: 940-987.
32. Mackey, A.C., Green, L., Liang, L.C., Dinndorf, P. and Avigan, M. ( 2007) Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 44: 265-267.
33. Markowitz, J., Grancher, K., Kohn, N., Lesser, M. and Daum, F. ( 2000) A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 119: 895-902.
34. Masunaga, Y., Ohno, K., Ogawa, R., Hashiguchi, M., Echizen, H. and Ogata, H. ( 2007) Meta-analysis of risk of malignancy with immunosuppressive drugs in inflammatory bowel disease. Ann Pharmacother 41: 21-28.
35. Modigliani, R., Mary, J.Y., Simon, J.F., Cortot, A., Soule, J.C., Genere, J.P. et al. (1990) Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology 98: 811-818.
36. Munkholm, P., Langholz, E., Davidsen, M. and Binder, V. ( 1995) Disease activity in a regional cohort of Crohn's disease patients. Scand J Gastroenterol 30: 699-706.
37. Olaison, G., Sjodahl, R. and Tagesson, C. ( 1990) Glucocorticoid treatment in ileal Crohn's disease: relief of symptoms but not of endoscopically viewed inflammation. Gut 31: 325-328.
38. Oren, R., Arber, N., Odes, S., Moshkowitz, M., Keter, D., Pomeranz, I. et al. (1996) Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology 110: 1416-1421.
39. Pearson, D.C., May, G.R., Fick, G.H. and Sutherland, L.R. ( 1995) Azathiorpine and 6-mercaptopurine in Crohn's disease. A meta-analysis. Ann Intern Med 123: 132-142.
40. Peyrin-Biroulet, L., Deltenre, P., Ardizzone, S., D'Haens, G., Hanauer, S.B., Herfarth, H. et al. (2009) Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis. Am J Gastroenterol 104: 2089-2096.
41. Prefontaine, E., Sutherland, L.R., MacDonald, J.K. and Cepoiu, M. ( 2009) Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database of Systematic Reviews 1: CD000067. DOI:10.1002/14651858. CD000067.pub2.
42. Punati, J., Markowitz, J., Lerer, T., Hyams, J., Kugathasan, S., Griffiths, A. et al. (2008) Effect of early immunomodulator use in moderate to severe pediatric Crohn's disease. Inflamm Bowel Dis 14: 949-954.
43. Rutgeerts, P., Feagan, B.G., Lichtenstein, G.R., Mayer, L.F., Schreiber, S., Colombel, J.F. et al. (2004) Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 126: 402-413.
44. Rutter, M., Saunders, B., Wilkinson, K., Rumbles, S., Schofield, G., Kamm, M. et al. (2004) Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 126: 451-459.
45. Salliott, C. and van der Heijde, D. (2009) Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis 68: 1100-1104.
46. Sandborn, W.J., Hanauer, S.B., Rutgeerts, P., Fedorak, R.N., Lukas, M., MacIntosh, D.G. et al. (2007) Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 56: 1232-1239.
47. Sandborn, W.J., Rutgeerts, P., Reinisch, W., Kornbluth, A., Lichtiger, S., D'Haens, G. et al. (2008) SONIC: a randomized, doubleblind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Am J Gastroenterology 103: S436 [abstract].
48. Sandborn, W.J., Sutherland, L.R., Pearson, D., May, G., Modigliani, R. and Prantera, C. ( 2000) Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews 3: CD000545. DOI: 10.1002/14651858.CD000545.
49. Siegel, C.A., Marden, S.M., Persing, S.M., Larson, R.J. and Sands, B.E. (2009) Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol 7: 874-881.
50. Timmer, A., McDonald, J.W.D. and MacDonald, J.K. ( 2007) Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 1: CD000478. DOI: 10.1002/14651858.CD000478.pub2.
51. Travis, S.P., Stange, E.F., Lémann, M., Oresland, T., Chowers, Y., Forbes, A. et al. (2006) European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 55(Suppl. I): i16-i35.
52. Travis, S.P.L., Stange, E.F., Lémann, M., Oresland, T., Bemelman, W.A., Chowers, Y. et al. (2008) European evidence-based consensus on the management of ulcerative colitis: current management. J Crohn's Colitis 2: 24-62.
53. van Assche, G., Magdelaine-Beuzelin, C., D'Haens, G., Baert, F., Noman, M., Vermeire, S. et al. (2008) Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 134: 1861-1868.
54. Velayos, F.S., Terdiman, J.P. and Walsh, J.M. ( 2005) Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 100: 1345-1353.
55. Vermeire, S., Noman, M., van Assche, G., Baert, F., D'Haens, G., Rutgeerts, P. et al. (2007) Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 56: 1226-1231.